Plasminogen Activator Inhibitor-1 as a Therapeutic Target for Healthy Longevity, Immunosenescence, and Age-Related Disease: Translational Development of the Small-Molecule Inhibitor TM5614
Mohamed Abdelhakim, Toshio Miyata · 2026
Read Plasminogen Activator Inhibitor-1 as a Therapeutic Target for Healthy Longevity, Immunosenescence, and Age-Related Disease: Translational Development of the Small-Molecule Inhibitor TM5614 by Mohamed Abdelhakim, Toshio Miyata (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13204133.txt.
Description
Mohamed Abdelhakim and Toshio Miyata review a clotting brake as a target for healthy aging in a 2026 paper. The protein, PAI-1, stops the enzymes that dissolve clots. It also drives scarring, metabolic trouble, cancer growth, and cell aging, the authors argue.
They frame PAI-1 as a checkpoint of immune aging: a node where worn-out and inflamed cells reinforce each other. Structure-guided work has yielded small drugs that block it. One, TM5614, can be taken by mouth and has reached clinical testing. Animal studies show gains against clots, scarring, swelling, and aging signs. Early human studies are now probing safety and effect, with longer life in view.
Catalog record
| CREATOR | Mohamed Abdelhakim, Toshio Miyata |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |